What does this research mean for the field?

Higher red cell distribution width (RDW) is independently associated with increased risks of all-cause mortality, cardiovascular disease, cerebrovascular disease, and chronic kidney disease in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate whether red cell distribution width (RDW), a routine hematologic marker, independently predicts adverse clinical outcomes and mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

August 27, 2026AntioxidantsOpen Access

Red Cell Distribution Width as an Independent Prognostic Biomarker in MASLD

View Full Paper

Ask AI

Bookmark

Authors

TRTom RyuSoonchunhyang University JLJaejun LeeCatholic University of Korea JHJi Won HanSeoul National University Bundang Hospital

Discussion

Member takes

Overview

Cohort study reveals red cell distribution width predicts mortality and vascular complications in MASLD, highlighting its value as an accessible prognostic biomarker.

Key Points

To evaluate whether red cell distribution width (RDW), a routine hematologic marker, independently predicts adverse clinical outcomes and mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
Analyzed 352,623 UK Biobank participants, including 165,700 individuals with MASLD, over a median follow-up of 13.6 years.
Evaluated RDW continuously and categorically using Cox proportional hazards regression, restricted cubic splines, inverse probability treatment weighting, landmark, competing risk, and mediation analyses.
Each 1% increase in RDW was independently associated with higher all-cause mortality (HR 1.14, p < 0.001).
Each 1% increase in RDW also predicted elevated risks of cardiovascular disease (HR 1.07, p < 0.001), cerebrovascular disease (HR 1.07, p < 0.001), and chronic kidney disease (HR 1.09, p < 0.001).

Cite This Study

Ryu et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe99e10c91c1e926215eb https://doi.org/10.3390/antiox15091065

View Full Paper

Ask AI

Bookmark

August 27, 2026AntioxidantsOpen Access

Red Cell Distribution Width as an Independent Prognostic Biomarker in MASLD

View Full Paper

Ask AI

Bookmark

Authors

TRTom RyuSoonchunhyang University JLJaejun LeeCatholic University of Korea JHJi Won HanSeoul National University Bundang Hospital

Discussion

Member takes

Overview

Cohort study reveals red cell distribution width predicts mortality and vascular complications in MASLD, highlighting its value as an accessible prognostic biomarker.

Key Points

To evaluate whether red cell distribution width (RDW), a routine hematologic marker, independently predicts adverse clinical outcomes and mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
Analyzed 352,623 UK Biobank participants, including 165,700 individuals with MASLD, over a median follow-up of 13.6 years.
Evaluated RDW continuously and categorically using Cox proportional hazards regression, restricted cubic splines, inverse probability treatment weighting, landmark, competing risk, and mediation analyses.
Each 1% increase in RDW was independently associated with higher all-cause mortality (HR 1.14, p < 0.001).
Each 1% increase in RDW also predicted elevated risks of cardiovascular disease (HR 1.07, p < 0.001), cerebrovascular disease (HR 1.07, p < 0.001), and chronic kidney disease (HR 1.09, p < 0.001).

Cite This Study

Ryu et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe99e10c91c1e926215eb https://doi.org/10.3390/antiox15091065

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark